Intradermal administration of a HLA-DR4-restricted native peptide derived from proinsulin (C19-A3) allowed maintenance of C-peptide levels in new-onset T1D over a 6-month treatment and resulted in increased frequencies of IL-10-expressing T cells [MonoPepT1De, (21, 22)]. The gene discussed is IL10; the disease is type 1 diabetes mellitus.